![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Reclassifies Influenza Test Systems as Class II
FDA Reclassifies Influenza Test Systems as Class II
![](https://www.fdanews.com/ext/resources/test/Device_Images4/BlueBall.jpg?t=1433877334&width=430)
The FDA has reclassified antigen-based rapid influenza virus antigen detection test systems (RIDTs) from Class I to Class II devices and has introduced special controls aimed at improving the quality of testing.
There is evidence that the currently available antigen-based RIDTs, which are widely used in non-clinical laboratory settings, are performing poorly, resulting in many misdiagnosed cases, the agency said.
In addition to requiring premarket notification, the final order requires special controls that:
- Identify the minimum acceptable performance criteria;
- Require use of an FDA-accepted comparator method for establishing the performance of new antigen based RIDTs;
- Require annual analytical reactivity testing of contemporary influenza strains; and
- Require analytical reactivity testing of newly emerging strains under certain situations involving an emergency or potential for an emergency. — Jeff Kinney
Upcoming Events
-
11Jul
-
18Jul
-
21Oct